Current Report Filing (8-k)
February 23 2021 - 4:17PM
Edgar (US Regulatory)
false 0001159036 0001159036 2021-02-23 2021-02-23
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 23, 2021
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Commission File Number 001-32335
|
|
|
Delaware
|
|
88-0488686
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
11388 Sorrento Valley Road
San Diego
California
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(858) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.001 par value
|
|
HALO
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On February 23, 2021, Halozyme Therapeutics, Inc. (the “Company”) issued a press release announcing that it proposes to offer, subject to market conditions and other factors, $500 million aggregate principal amount of convertible senior notes due 2027 (the “Convertible Notes”). The Company expects to grant to the initial purchasers an option to purchase up to an additional $75 million aggregate principal amount of Convertible Notes. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
HALOZYME THERAPEUTICS, INC.
|
|
|
|
|
February 23, 2021
|
|
|
|
By:
|
|
/s/ Mas Matsuda
|
|
|
|
|
Name:
|
|
Mas Matsuda, Esq.
|
|
|
|
|
Title:
|
|
Senior Vice President, General Counsel and
Corporate Secretary
|
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Sep 2023 to Sep 2024